Oral Capsule Speeds Relief From Hereditary Angioedema

In a phase 3 trial, people with hereditary angioedema reached symptom relief much faster with deucrictibant than with placebo.

Updated on Nov. 2, 2026 in Allergies

Bold flat-color editorial illustration of a single smooth amber and cream capsule centered on a deep navy field, evoking a new oral treatment for hereditary angioedema.
Deucrictibant, an oral bradykinin B2 receptor antagonist, cut time to symptom relief for hereditary angioedema attacks versus placebo in a phase 3 trial, with FDA review set for April 23, 2027. AI Illustration. Upload story photo >

A new immediate-release capsule of deucrictibant shortened the time to symptom relief for hereditary angioedema attacks compared with placebo in a phase 3 trial. The U.S. FDA is reviewing the application, with a target action date of April 23, 2027, for adults and adolescents living with this rare condition.

Why it matters

Hereditary angioedema causes sudden, unpredictable swelling attacks, so faster relief during an episode is a central goal for people managing the disease. The results add an oral option to the treatment landscape if the drug is approved.

This phase 3 randomized, double-blind, placebo-controlled crossover trial enrolled 134 patients, with 88 treating one attack with deucrictibant and another with placebo. Deucrictibant produced symptom relief at a median of 1.28 hours versus more than 12 hours for placebo, and 60% of treated attacks reached complete symptom resolution at 24 hours versus 15% for placebo.

The players

University of California, San Diego

A public research university whose researchers led the RAPIDe-3 trial of deucrictibant for hereditary angioedema.

The details

Deucrictibant is an oral bradykinin B2 receptor antagonist, meaning it blocks the receptor that bradykinin uses to drive the vascular leakage behind hereditary angioedema swelling. In the trial, symptom relief was measured with the Patient Global Impression of Change rating within 12 hours of dosing. Six treatment-emergent adverse events related to the drug occurred within 3 days, no serious or severe related adverse events were reported, and no patient discontinued because of adverse events.

Timeline

  1. The FDA's target action date for the immediate-release decision is April 23, 2027.

Health Landscape

Deucrictibant would be the first approved oral bradykinin B2 receptor antagonist if the FDA approves the immediate-release capsule, according to lead researcher Riedl. An extended-release tablet, which showed an 83% monthly attack rate reduction versus placebo, is also under investigation.

People living with hereditary angioedema may want to ask their physician whether a faster-acting oral option could fit their attack-management plan once it is available. Because the trial results come from a specific population of patients aged at least 12, anyone considering a change in treatment should discuss it with their doctor first.

The takeaway

Faster symptom relief is a meaningful goal for people with hereditary angioedema, and this trial shows it can be achieved in a placebo-controlled study. Ask your physician about attack-management options and track when new treatments reach your region.

What happens next

The FDA is reviewing the new drug application for deucrictibant immediate-release, with a target action date of April 23, 2027.

Further reading

For broader context on the immune-driven swelling disorders behind these attacks, explore our Allergies coverage.

Source note: This article includes information reported by Healio.